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INTRODUCTION {#s1}
============

Meningitis is a life-threatening inflammatory disease of the brain and spinal cord that can be caused by bacterial, viral, fungal, and parasitic infections.^[@b1]^ The greatest burden occurs in sub-Saharan Africa, bearing half of the estimated 2.8 million cases and 58% of the 318,400 deaths estimated annually.^[@b2]^ Up to a quarter of bacterial meningitis survivors may be left with sequelae including cognitive impairment, paralysis, and hearing loss.^[@b3]^ Children younger than 5 years are disproportionately affected.^[@b2]^

Before the rollout of effective conjugate vaccines, *Neisseria meningitidis*, *Haemophilus influenzae* type B (Hib), and *Streptococcus pneumoniae* accounted for the bulk of meningitis cases in children.^[@b2],[@b4],[@b5]^ However, as vaccines for these three bacterial pathogens have been introduced across West Africa, the relative importance of other causes of meningitis such as gram-negative bacteria, ß-hemolytic streptococci, *Staphylococcus*, *Listeria*, fungi, and viruses has increased.^[@b2]^ The broad spectrum of meningeal pathogens, some of which require special therapy or should not receive antibiotics, poses new challenges for rapid and accurate diagnosis.

Historically, meningitis diagnosis and surveillance are hindered by the very low pathogen yields from bacteriologic culture. Mwenda and colleagues reported that culture confirmation was less than 1% among 48,284 children younger than 5 years with suspected meningitis across 26 African countries.^[@b6]^ Accordingly, the WHO has recommended improved diagnostics and surveillance as key priorities on their road map to eliminate epidemic meningitis in Africa by 2030.^[@b7]^ A technical task force identified the need for a multiplex diagnostic tool with the capacity to simultaneously detect meningeal pathogens. Real-time polymerase chain reaction (PCR)--based tools have the capacity to detect meningeal pathogens with high sensitivity, specificity, and reproducibility.^[@b8]--[@b10]^ Several meningitis/encephalitis molecular multiplex PCR assays have been developed, some of which are commercially available.

In this work, because of the ability to customize the pathogens we wished to detect, we used the TaqMan Array Card (TAC). TAC is Card is a compartmentalized probe-based real-time PCR system that uses microfluidic technology, with PCRs configured in a 384-well array format. TaqMan Array Card can be used to simultaneously and accurately detect bacterial, viral, protozoan, and fungal pathogens using very small volumes of the clinical specimen. TAC has been used to improve the diagnostic yield in other low-resource settings, for example, determining the etiology of febrile illness and sepsis in East Africa^[@b11],[@b12]^ and South Africa.^[@b13]^ Saha and colleagues used the TAC platform to determine the etiology of community-acquired neonatal infections in South Asia.^[@b14]^ We have previously used the TAC platform to improve the case-level and population-level ascertainment of the causes of diarrhea in multiple countries.^[@b15]^

We therefore used a customized TAC assay that targets 35 meningitis and encephalitis pathogens for case ascertainment in cerebrospinal fluid (CSF) specimens collected from five West African countries among children younger than 5 years with suspected meningitis. Our study included suspected meningitis cases that occurred between 2017 and 2018, after the rollout of the pneumococcal conjugate vaccine (PCV), the meningococcal A protein--polysaccharide conjugate vaccine (MenAfriVac), and the Hib conjugate vaccine in all five countries. This study therefore allowed an examination of the meningitis pathogens that countries should prioritize.

METHODS {#s2}
=======

Surveillance design and sample collection.
------------------------------------------

The WHO Collaborating Center for New Vaccines Surveillance (WHO CC NVS) hosted at the Medical Research Council Unit, the Gambia, at the London School of Hygiene and Tropical Medicine (MRCG at LSHTM) also serves as the WHO Regional Reference laboratory (WHO RRL) for invasive bacterial diseases. The WHO CC and RRL support the WHO-coordinated Pediatric Bacterial Meningitis Surveillance (PBM) network across 10 countries in West and Central Africa, a region of the world with high under-five mortality. The WHO-coordinated PBM enrolled children younger than 5 years with suspected meningitis presenting at sentinel sites. The sentinel sites participating in the PBM network are pediatric teaching and referral hospitals. The six sentinel sites included in this study were in Senegal (Dakar),^[@b16]^ Ghana (Kumasi and Accra),^[@b17]^ Togo (Lome),^[@b18]^ Nigeria (Enugu),^[@b19]^ and Niger (Niamey),^[@b20]^ all countries at risk of meningitis epidemics.^[@b21]^ The sentinel sites in Niger and Senegal fall within the hyperendemic region of the meningitis belt. The sentinel sites were selected for the TAC study based on the quality of the surveillance data and the number of samples available for TAC testing.^[@b6]^

Suspected cases were any child aged 0--59 months admitted to a sentinel hospital conducting surveillance with a sudden onset of fever (\> 38.5°C rectal or 38.0°C axillary) and one of the following signs: neck stiffness, altered consciousness (with no other alternative diagnosis), or other meningeal signs.^[@b22],[@b23]^ Lumbar puncture was performed to obtain CSF from suspected cases. Standard bacteriology, cytology and biochemistry were performed on CSF specimens at the sentinel sites.^[@b24]^ The remaining CSF specimens were stored at −20°C until they were shipped on dry ice to the WHO RRL and stored at −80°C until testing. For this pilot, we tested all residual CSF with volumes of at least 150 µL collected between January 2017 and June 2018 from the sentinel sites.

Ethics review and approvals.
----------------------------

The standard operating procedures and protocols for this pilot were approved by The joint Gambia Government/MRCG at LSHTM Ethics Committee. The TAC diagnostics were provided by the University of Virginia, VA, whose IRB approved the grant proposal. Approval was granted by the Ministries of Health of the participating countries to test CSF samples collected as part of ongoing routine surveillance for vaccine-preventable diseases.

Laboratory procedures.
----------------------

Triplex real-time PCR detection of *N. meningitidis*, *S. pneumoniae*, and *H. influenzae* was performed at the WHO CC NVS as described previously.^[@b25],[@b26]^ For this pilot, we assessed etiologies using a custom-made TAC (Thermo Fisher Scientific, Carlsbad, CA) that compartmentalized probe-based quantitative polymerase chain reaction (qPCR) assays for 35 pathogens selected based on the global, regional, and national estimates of meningitis and sepsis.^[@b2],[@b27]^ The TAC assay included 15 bacteria (*Bartonella* spp.; *Brucella* spp.; *Escherichia coli*/*Shigella* spp.; *H. influenzae*; Hib; *Klebsiella pneumoniae*; *Leptospira* spp.; *Listeria monocytogenes*; *Mycoplasma pneumoniae*; *Mycobacterium tuberculosis*; *N. meningitidis*; *N. meningitidis* serogroups A, B, C, W, X, and Y; *Rickettsia* spp.; *Salmonella enterica*; *Staphylococcus aureus*; *Streptococcus agalactiae*; and *S. pneumoniae*), 17 viruses (adenovirus, cytomegalovirus (CMV), dengue, Epstein--Barr virus (EBV), enterovirus, human herpesvirus 6, herpes simplex virus 1, herpes simplex virus 2, human immunodeficiency virus (HIV) I, HIV II, influenza A, measles, mumps, parechovirus, parvovirus B19, varicella zoster virus, and West Nile virus), one fungus (*Cryptococcus neoformans*), and two protozoans (*Plasmodium* spp., *Plasmodium falciparum*, and *Toxoplasma gondii*). Primer and probe sequences were adapted largely from Onyango and colleagues^[@b28]^ as well as from our prior work and other publications using the same platform.^[@b11],[@b29]--[@b31]^ New assays developed and validated for this project are listed in [Supplemental File 1](/content/journals/10.4269/ajtmh.19-0466#supplementary_data). For each specimen, at least 150 µL but up to 200 µL of the CSF underwent nucleic acid extraction using QIAamp MinElute Virus Spin kit (Qiagen, Hilden, Germany) following the manufacturer's instruction. Samples with less than 150 µL of the CSF were excluded. When the sample volume was less than 200 µL, 0.9% sodium chloride was supplemented to bring the volume to 200 µL. This affected \< 3% of specimens tested. Two external controls, bacteriophage MS2 and phocine herpesvirus, were added to assess extraction and amplification efficiency. We included one extraction blank per batch of extraction to monitor contamination. Purified nucleic acids were subjected to TAC qPCR. The reaction mixes contained 25 µL of TaqMan Fast Virus 1-Step Master Mix and 75 µL of total nucleic acid extract or nuclease-free water as negative control. We included one negative control per 10 cards to exclude laboratory contamination. Amplification involved a reverse transcription step at 50°C for 10 minutes, and then an initial denaturation step at 95°C for 20 seconds, followed by 40 cycles of 95°C for 3 seconds and 60°C for 30 seconds. All detections with a quantification cycle (Cq) value greater than 35 were considered negative. Valid results required proper functioning of controls and excluded data flagged by the QuantStudio^™^ Real Time PCR software version 1.2(Thermo Fisher Scientific, Carlsbad, CA), and 99% of specimens had valid results. The WHO RRL participates in the WHO External Quality assessment program for the invasive bacterial vaccine preventable diseases, UK NEQAS for Microbiology (<http://www.ukneqasmicro.org.uk>).

Statistical analysis.
---------------------

Participant characteristics were summarized using proportions for categorical variables and medians for continuous variables. We examined associations using chi-square/Fisher's exact and Mann--Whitney U test for categorical and continuous variables, respectively. Odds ratios were calculated to assess the pathogen association with mortality where possible. Accuracy was determined with reference to the triplex real-time PCR results. All tests were two-tailed, at 5% significance level. Analyses were performed using SPSS (version 25.0; IBM Corp, Armonk, NY) and Stata statistical software: Release 12 (StataCorp LP, College Station, TX).

RESULTS {#s3}
=======

During the study period, a total of 1,535 suspected meningitis cases were reported across the sentinel sites, and 1,088 CSF specimens were sent to the WHO RRL for molecular testing. Reasons for CSF samples not being sent to the WHO RRL vary but include 1) lumbar puncture not performed, 2) insufficient volumes of CSF, and 3) missing CSF samples. Of the CSF samples received at the RRL, 717/1088 (65%) had sufficient volume to perform TAC analysis, and, of these, 711/717 (99%) yielded valid TAC results. The characteristics of patients with valid TAC results are shown in [Table 1](#t1){ref-type="table"}. The surveillance site in Ghana enrolled predominantly neonates (median age, \< 1 month), whereas in the other sites, toddlers or young children accounted for the bulk of suspected cases (median ages at other sites, 11--36 months). A majority (67%) of children in Ghana reported having received antibiotics before lumbar puncture, whereas prior antibiotic treatment was less commonly reported at the other sites (0--35%). The CSF samples were collected on average 3 days after the onset of the illness. Most children did not have significant CSF pleocytosis (87% had CSF whole blood cell count (WBC) \< 10). Among the 605 patients with outcome at discharge information, 9.8% died.

###### 

Clinical characteristics of the suspected meningitis cases enrolled in surveillance

                                                                Ghana              Nigeria            Niger              Senegal            Togo
  ------------------------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------
  Suspected meningitis cases reported\*                         351                177                320                146                541
  CSF specimens tested by TAC[†](#t1fn1){ref-type="table-fn"}   205                139                31                 31                 305
  Gender                                                                                                                                    
   Male, *n* (%)                                                115 (56)           82 (59)            18 (58)            19 (61)            176 (58)
  Age (months)[‡](#t1fn2){ref-type="table-fn"}                                                                                              
   Median (months)                                              0.6                23                 36                 11                 16
   \< 1, *n* (%)                                                123 (60)           10 (7.2)           0                  8 (26)             77 (25)
   1--23, *n* (%)                                               59 (29)            55 (40)            11 (36)            13 (42)            100 (33)
   24--59, *n* (%)                                              22 (11)            74 (53)            20 (65)            10 (32)            128 (42)
  Collection date                                               01/2017--02/2018   01/2017--06/2018   04/2017--03/2018   01/2017--12/2017   01/2017--02/2018
  Median days between onset and CSF collection (range)          3 (0--26)          5 (0--33)          1 (0--5)           4.5 (0--61)        3 (0--30)
  Antibiotic usage, *n* (%)                                                                                                                 
   Yes                                                          137 (71)           0                  0                  12 (40)            56 (35)
   No                                                           56 (29)            121 (100)          1                  18 (60)            104 (65)
  CSF white blood count (cells/mm^3^), *n* (%)                                                                                              
   \< 10                                                        179 (90)           139 (10)           23 (74)            8 (27)             270 (89)
   10--100                                                      10 (5.0)           0                  6 (19)             9 (30)             27 (8.9)
   \> 100                                                       11 (5.5)           0                  2 (6.5)            13 (43)            6 (2.0)
  Cerebrospinal fluid glucose (mg/dL), *n* (%)                                                                                              
   \< 40                                                        22 (18)            8 (5.8)            6 (40)             11 (37)            24 (9.1)
   40--100                                                      101 (80)           126 (91)           9 (60)             19 (63)            191 (72)
   \> 100                                                       3 (2.4)            5 (3.6)            0                  0                  50 (19)
  Outcome at discharge, *n* (%)                                                                                                             
   Died                                                         5 (2.4)            22 (16)            5 (16)             4 (13)             23 (11)
   Discharged alive                                             196 (96)           103 (75)           13 (42)            22 (71)            164 (82)
   Transferred                                                  1 (0.5)            0                  13 (42)            3 (9.7)            0
   Left against medical advice                                  1 (0.)             12 (8.8)           0                  0                  14 (7.0)
   Pending discharge                                            2 (1.0)            0                  0                  2 (6.5)            0

\* Although there were a total of 1,535 suspected meningitis cases reported during the study period, 1088 CSF specimens were sent to the WHO RRL. Of these 1088 CSF specimens, 717 had sufficient volume for TAC testing. lumbar puncture was performed.

This excludes the six samples that failed in the TAC analysis.

Not all the information was available for all the patients. Percentage was calculated for the samples with the corresponding information available.

Pathogen detection by TAC.
--------------------------

Overall, 20% of the samples had at least one pathogen detected, including 10 bacterial pathogens, eight viral pathogens, and *Plasmodium*. The pathogen detection rate was 22% for Ghana, 24% for Nigeria, 29% for Niger, 45% for Senegal, and 8% for Togo. *Escherichia coli* was the most prevalent (4.8%, [Figure 1](#f1){ref-type="fig"}), followed by *S. pneumoniae* (3.5%) and *Plasmodium* (3.5%). One pathogen was detected in 15.6% of specimens, whereas 4.4% of specimens contained \> 1 pathogen. The period from illness onset to CSF collection was 3 days (interquartile range: 1--6). There was no difference in the duration of illness in those with pathogens detected versus those without (*P* \> 0.05).

![Overall pathogen detection in different age-groups among West African children younger than 5 years with suspected meningitis.](tpmd190566f1){#f1}

Comparison of TAC results with the triplex real-time PCR results.
-----------------------------------------------------------------

CSF culture was performed on 707 fresh CSF samples, for an overall 2.0% pathogen detection rate. Compared with the culture results, TAC detected the only *H. influenzae* case, all three *S. pneumoniae* cases, and one of the two *N. meningitidis* cases confirmed by culture (see [Supplemental Table](/content/journals/10.4269/ajtmh.19-0466#supplementary_data)).

In addition, 711 CSF samples were previously tested for *N. meningitidis*, *H. influenzae*, and *S. pneumoniae* using a triplex real-time PCR assay. The human *RNAse P* gene internal control failed in 249 specimens, and these results were censored according to the protocol. Of the 462 specimens with conclusive results, there were nine positive results by triplex real-time PCR. TAC detected 3/3 *N. meningitidis*, 4/5 *S. pneumoniae*, and 0/1 *H. influenzae* results; however, this latter specimen had a high Cq of 35.8 by triplex real-time qPCR, indicative of a low *H. influenzae* bacterial load. Therefore, TAC yielded an overall sensitivity of 78% (7/9) and 99% specificity (1,358/1,377) versus triplex real-time PCR yet detected an additional 17 *S. pneumoniae* and two *N. meningitidis* cases. TAC also detected an additional 22 *S. pneumoniae* and four *N. meningitidis* cases compared with culture. Thus, the overall yield of a potential etiology was 20% (143/711) by TAC versus 2.0% by culture and 2.4% by triplex real-time PCR.

Pathogen detection by country and by age.
-----------------------------------------

[Table 2](#t2){ref-type="table"} shows the distribution of pathogens in the five countries. Bacteria were the dominant pathogens across all the sites, except Togo, where *Plasmodium* was the leading pathogen detected in 5.0% of the specimens. The most common pathogen was *S. pneumoniae* in Ghana (6.3%) and Niger (13%), whereas it was *E. coli* in Nigeria (14%) and Senegal (16%). Among 220 neonates (aged 0--28 days), 17% had at least one pathogen detected, dominated by the gram-negative bacterial pathogens ([Figure 1](#f1){ref-type="fig"}). *Escherichia coli*, *K. pneumoniae*, and *S. pneumoniae* were consistently detected across all age-groups. *Plasmodium* was exclusively detected in 1- to 59-month-old children. Similarly, more viruses were detected in older age-groups, in particular parvovirus B19.

###### 

Pathogen detection (%) in the five countries

                                  Ghana (*n* = 205)   Nigeria (*n* = 139)   Niger (*n* = 31)   Senegal (*n* = 31)   Togo (*n* = 305)
  ------------------------------- ------------------- --------------------- ------------------ -------------------- ------------------
  *Escherichia coli*              5 (2.4)             **20 (14)**           --                 **5 (16)**           4 (1.3)
  *Plasmodium*                    3 (1.5)             5 (3.6)               2 (6.5)            --                   **15 (4.9)**
  *Streptococcus pneumoniae*      **13 (6.3)**        4 (2.9)               **4 (13)**         3 (9.7)              1 (0.3)
  *Staphylococcus aureus*         8 (3.9)             2 (1.4)               --                 3 (9.7)              8 (2.6)
  *Klebsiella pneumoniae*         7 (3.4)             8 (5.7)               2 (6.5)            2 (6.5)              --
  Parvovirus B19                  --                  8 (5.7)               1 (3.2)            1 (3.2)              2 (0.7)
  *Streptococcus agalactiae*      6 (2.9)             1 (0.7)               --                 --                   --
  Dengue                          3 (1.5)             --                    --                 1 (3.2)              2 (0.7)
  *Neisseria meningitidis*        1 (0.5)             1 (0.7)               3 (9.7)            --                   1 (0.3)
  CMV                             2 (1.0)             --                    --                 1 (3.2)              2 (0.7)
  EBV                             --                  2 (1.4)               1 (3.2)            --                   1 (0.3)
  HIV I                           --                  1 (0.7)               1 (3.2)            --                   2 (0.7)
  Enterovirus                     3 (1.5)             --                    --                 --                   --
  HHV 6                           2 (1.0)             --                    --                 --                   1 (0.3)
  Mumps                           1 (0.5)             --                    --                 --                   1 (0.3)
  HIV II                          --                  --                    --                 --                   1 (0.3)
  *Bartonella*                    1 (0.5)             --                    --                 --                   --
  *Haemophilus influenzae*        --                  --                    1 (3.2)            --                   --
  *Mycobacterium tuberculosis*    --                  1 (0.7)               --                 --                   --
  *Rickettsia*                    --                  1 (0.7)               --                 --                   --
  Total pathogen detection rate   45 (22)             33 (24)               9 (29)             14 (45)              24 (8.0)

Bold values indicate the most prevalent pathogen for each country.

Effect of antibiotics usage on pathogen detection.
--------------------------------------------------

Antibiotic usage information was available for 71% of the patients. Forty-one percent of patients reported antibiotic treatment before admission, and the reported usage varied greatly by site. Although overall bacterial pathogen detection was similar with or without antibiotics, there were considerable differences for *E. coli* and *Plasmodium* detection, with lower rates in those that reported having received antibiotics: 3.4% versus 8.0% for *E. coli* (*P* = 0.038) and 0.5% versus 3.7% for *Plasmodium* (*P* = 0.033).

Other laboratory testing.
-------------------------

Probable meningitis was pre-classified as a suspected meningitis case with turbid appearance or WBC \> 100 cells/mm^3^ or a WBC 10--100 cells/mm^3^ with elevated protein (\> 100mg/dl) or decreased glucose (\< 40mg/dL).^[@b32]^ Among the 20 CSF samples from these probable meningitis cases, a high rate (55%, 11/20) were positive for bacterial pathogens, including one *E. coli*, five *K. pneumoniae*, one *N. meningitidis*, and four *S. pneumoniae*. In addition, the pathogen loads (indicated by the real-time PCR Cq) in these specimens were significantly higher than the quantity in those with low white blood cell counts and high glucose concentration (Mann--Whitney U test, *P* = 0.035). As expected, among samples with low white blood count (\< 10 cells/mm^3^), the detection rate was 19% (117/618). We included some *N. meningitidis* serogrouping on the TAC as well. Of the six *N. meningitidis* positives, we identified one serogroup A (Ghana), three serogroup C (one from Togo and two from Nigeria), one serogroup W (Niger), and one untyped likely due to low target concentration (Nigeria).

Pathogen association with mortality.
------------------------------------

Among the 605 patients with outcome at discharge information, 9.8% died, with the lowest rate in Ghana (2.4%) and the highest in Niger and Nigeria (16% each). [Table 3](#t3){ref-type="table"} shows the mortality rates by pathogen. Detection of HIV and *Plasmodium* was associated with the highest fatality rates of 50% and 29%, respectively.

###### 

Pathogen association with mortality

                               Total   Fatality rate before discharge (%)
  ---------------------------- ------- ------------------------------------
  CMV                          4       25
  Dengue                       5       0
  *Escherichia coli*           28      18
  Enterovirus                  3       0
  HHV 6                        3       33
  HIV                          4       50
  *Klebsiella pneumoniae*      15      20
  *Neisseria meningitidis*     5       0
  Parvovirus B19               10      10
  *Plasmodium*                 17      29
  *Streptococcus agalactiae*   7       14
  *Staphylococcus aureus*      19      11
  *Streptococcus pneumoniae*   23      17
  No pathogen                  414     8

DISCUSSION {#s4}
==========

Childhood meningitis poses a major public health challenge globally and is particularly problematic because it has diverse infectious etiologies. This work shows the increased diagnostic yield of using a pan-molecular syndromic TAC, which revealed a diversity of 19 pathogens in CSF from five countries in West Africa. Using the TAC assay increased the diagnostic yield of meningitis to 20%, an approximate 10-fold increase over bacterial culture or a triplex real-time PCR assay.^[@b25],[@b26]^ The sensitivity of TAC versus the earlier methods that were performed was very good, and many more detections were found with TAC.

Several findings were notable. First, the TAC assay greatly increased the detection of the pneumococcus versus the prior triplex real-time PCR that was performed. Both the triplex real-time PCR assay and the TAC assay targeted the autolysin encoding gene (*lytA*) of the *S. pneumoniae.* Therefore, the improved pneumococcal detection with TAC was likely related to the greater volume of CSF tested and the DNA extraction protocol. The pneumococcus is an extremely important pathogen, was common across the age strata, and the most common pathogen detected in CSF in Ghana and Niger. Ghana had an earlier introduction of the 13-valent PCV (PCV13) in 2012, achieving coverage of 90% by 2016. However, Ghana has experienced large outbreaks of pneumococcal meningitis after PCV introduction.^[@b24]^ Implementation of the TAC assay in routine surveillance would enhance the monitoring of pneumococcal meningitis in the post-PCV era across the subregion. To further enhance such surveillance, it would be useful to examine serotypes using direct molecular tools,^[@b33]^ and these can be incorporated into a future TAC version. Worth noting is that TAC is easy to use and modular for customized use,^[@b8]^ with a reagent cost of ∼\$60/sample and 3-hour running time from sample to results.

Over the last century, populations in Africa's meningitis belt, which includes Senegal, Togo, Niger, and the northern regions of Ghana and Nigeria, have borne the brunt of meningococcal meningitis outbreaks.^[@b34]^ Serogroup A meningococcus was the dominant cause of meningitis outbreaks until the rollout of MenAfriVac across countries in the meningitis belt between 2010 and 2018.^[@b5]^ However, the emergence of serogroup C, W, and X strains with epidemic potential threaten the success of MenAfriVac.^[@b35]--[@b38]^ Using the TAC assay, we confirmed one serogroup W and three serogroup C meningitis cases. A meningococcal serogroup A meningitis case was also detected and warrants further investigation. The meningococcal capsular typing included in the TAC assay could be of great value during outbreak emergencies because reactive vaccination campaigns depend on rapid and accurate identification of the meningococcal serogroup causing the outbreak.^[@b39]^

The TAC assay also highlighted the potential importance of *E. coli*, particularly in Nigeria and Senegal. *Escherichia coli* is well known to be a common cause of neonatal meningitis.^[@b40]^ The high rate of gram-negative pathogens such as *E. coli* and *K. pneumoniae*, particularly in older age categories, was notable. Many of these specimens had highly meningitic CSF indices; thus, we suspect these PCR diagnoses are accurate. Although gram-negative meningitis is less common in older children, comorbidities such as malnutrition may have contributed to this finding.^[@b41],[@b42]^ *Escherichia coli* culture--positive rates of 1--16% have been reported in other studies of childhood meningitis in Nigeria and Ghana.^[@b43]--[@b45]^ The gram-negative bacteria causing meningitis is also concerning because they are associated with the highest rates of antimicrobial resistance.^[@b46]^

*Staphylococcus aureus* was also quite common, particularly in the first month of life. This pathogen is often associated with meningitis and sepsis in the neonatal period, particularly in low birth weight infants (information we did not collect).^[@b47]^ However, *S. aureus* has been commonly reported as a cause of meningitis by culture in recent reports from Nigeria.^[@b48]^

Beyond bacteria, there were a number of additional interesting findings. There was substantial *Plasmodium* in the CSF. We suspect these *Plasmodium* detections reflected cerebral malaria, particularly given the high mortality. Indeed, cerebral malaria has been noted to be a major etiology in children with suspected meningitis,^[@b49]^ but it is usually diagnosed based on blood smear and clinical grounds. Notably, *Plasmodium* was not detected in individuals with meningitic CSF profiles, suggesting this was not meningitis per se. Although the detection of malaria in CSF could simply be due to blood contamination of CSF, we think this is unlikely. In one study, the detection of *Plasmodium* HRP-2 protein in CSF, but not plasma, was associated with high mortality in cerebral malaria; thus, DNA detection in the CSF is quite plausible.^[@b50]^ Parvovirus B19 was quite common in older children and is well known to be able to cause meningitis.^[@b51]^ Group B *Streptococcus* meningitis was also detected and found predominantly among neonates, which is consistent with previous findings.^[@b14],[@b52]^

This study has several limitations. First, this study used sentinel-based disease surveillance. Specimens collected through nationwide case-based surveillance systems for meningitis would have been ideal; however, this type of surveillance for meningitis is not operational in most of the West African countries active in the PBM surveillance. The MenAfriNet consortium which has supported the implementation of case-based meningitis surveillance in Burkina Faso, Chad, Mali, Niger, and northern Togo has demonstrated the utility of such efforts.^[@b53]^ The representativeness of the findings is also limited in that not all the CSF specimens were available for testing; for instance, only 19% of specimens from Senegal were available for TAC testing. There were also large differences in the age distributions of children presenting with suspected meningitis across the various countries. This means that any intercountry comparisons need to be interpreted with caution. Most of the suspected cases had white blood cell counts less than 10 cells/mm^3^ and glucose \> 40 mg/dL, which are not suggestive of probable meningitis. There may be several explanations for this which include overlap of the WHO meningitis case definition with other serious febrile illness. This could certainly be the case for Togo, where the dominant pathogen detected was *Plasmodium*. High rates of antibiotic treatment before lumbar puncture (e.g., 71% in Ghana) could also contribute to low white blood cell counts in children meeting the case definition.^[@b9]^

We found that 4.4% of specimens had coinfections, with the most common combinations including *Plasmodium* and a bacterium or a virus (CMV or EBV). Although there is evidence that viral and bacterial coinfections do occur in meningitis patients and may be associated with higher mortality,^[@b54]^ these findings warrant thorough investigation in future studies. The significance of CMV also needs further investigation.^[@b55]^

In summary, this meningitis TAC provided an abundance of useful information beyond culture and routine triplex PCR assays to understand the etiologies of meningitis in West African children. A cornerstone to defeating meningitis by 2030^[@b7]^ will be to ascertain the various causes of meningitis and implement the appropriate control and prevention strategies. Enhanced meningitis case ascertainment could be achieved through the implementation of better molecular detection in meningitis surveillance programs.

Supplemental files
==================

[Supplemental materials](/content/journals/10.4269/ajtmh.19-0566supplementary_data)
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